Underlying data for 'Serum Leucine-Rich Alpha-2 Glycoprotein Levels in Rheumatoid Arthritis and Spondyloarthritis: A Promising Biomarker'

This is a database of a cross-sectional data collected to evaluate serum leucine-rich alpha-2 glycoprotein levels in rheumatoid arthritis and spondyloarthritis. The subjects were recruited from the rheumatology polyclinic of Dr. Cipto Mangunkusumo National Central Public Hospital (Jakarta, Indonesia) from March to May of 2022. This study has received approval from the Research Ethics Committee of Faculty of Medicine Universitas Indonesia and Dr. Cipto Mangunkusumo National Central Public Hospital (KET-197/UN2.F1/ETIK/PPM.00.02/2022).
Patients aged over 18 years old with confirmed seropositive active rheumatoid arthritis, ankylosing spondylitis, and peripheral spondyloarthritis who gave their consent were recruited. Patients with other systemic autoimmune diseases, acute infectious diseases, liver disorders, and malignancies are excluded from the study. Patient characteristics, serum LRG (Human LRG ELISA Assay Kit, Immuno-Biological Laboratories Co., Ltd., Fujioka, Gunma, Japan; read with spectrophotometry at 450 nm), and serum CRP (cobas c 311 analyzer, Roche Holding AG, Basel, Switzerland) were recorded in this database.